Firmonertinib
Firmonertinib is an oral, brain-penetrant, mutant-selective inhibitor of EGFR. It targets a broad spectrum of EGFR mutations, including exon 20 insertions and the T790M resistance mutation. Firmonertinib is being developed as a first-line treatment for patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertions.
| Trivial name | Alflutinib, Furmonertinib, AST2818 |
| Catalog Number | E5881 |
| Molecular Formula | C10H16N2O4S3.HCl |
| CAS# | 1869057-83-9 |
| Inchi | InChI=1S/C10H16N2O4S3.ClH/c1-3-12-8-4-6(2)18(13,14)10-7(8)5-9(17-10)19(11,15)16;/h5-6,8,12H,3-4H2,1-2H3,(H2,11,15,16);1H/t6-,8-;/m0./s1 |
| Inchi Key | OSRUSFPMRGDLAG-QMGYSKNISA-N |
| SMILES | CCNC1CC(S(=O)(=O)C2=C1C=C(S2)S(=O)(=O)N)C.Cl |
| Size | 25mg |
| Supplier Page | http://www.selleckchem.com/products/firmonertinib.html |
| Additional Information | https://file.selleck.cn/downloads/struct/E5881-Firmonertinib-chemical-structure.png |